These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1003 related items for PubMed ID: 18510692

  • 21. Diagnosis and management of refractoriness to platelet transfusion.
    Schiffer CA.
    Blood Rev; 2001 Dec; 15(4):175-80. PubMed ID: 11792118
    [Abstract] [Full Text] [Related]

  • 22. [Can thrombocyte crossmatching improve the efficiency of platelet transfusion?].
    Weisbach V, Zeiler T, Zingsem J, Musch R, Heuft HG, Eckstein R.
    Beitr Infusionsther; 1990 Dec; 26():160-2. PubMed ID: 1703820
    [Abstract] [Full Text] [Related]

  • 23. Platelet transfusion refractoriness and anti-HLA immunization.
    Blandin L, Dougé A, Fayard A, Bay JO, Berlie G, Pereira B, Lemal R, Rouzaire P.
    Transfusion; 2021 Jun; 61(6):1700-1704. PubMed ID: 33709433
    [Abstract] [Full Text] [Related]

  • 24. Strategies for managing refractoriness to platelet transfusions.
    Dan ME, Schiffer CA.
    Curr Hematol Rep; 2003 Mar; 2(2):158-64. PubMed ID: 12901147
    [Abstract] [Full Text] [Related]

  • 25. The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non-selected haematological population of patients.
    Levin MD, van der Holt B, de Veld JC, Gratama JW, de Vries W, van't Veer MB.
    Vox Sang; 2004 Nov; 87(4):291-8. PubMed ID: 15585026
    [Abstract] [Full Text] [Related]

  • 26. Clinical aspects of platelet transfusion therapy.
    Murphy MF.
    Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():34-8. PubMed ID: 7841778
    [Abstract] [Full Text] [Related]

  • 27. Complement as an Immune Barrier in Platelet Transfusion Refractoriness.
    Meinke S, Karlström C, Höglund P.
    Transfus Med Rev; 2019 Oct; 33(4):231-235. PubMed ID: 31679761
    [Abstract] [Full Text] [Related]

  • 28. [Intrauterine transfusion in fetal alloimmunothrombocytopenia: comparison of maternal and fetal weight-adjusted IgG therapy with exclusive fetal thrombocyte transfusion].
    Giers G, Kroll H, Hoch J, Bald R, Bauer H, Kiefel V, Hansmann M, Hanfland P, Mueller-Eckhardt C, Scharf RE.
    Beitr Infusionsther Transfusionsmed; 1997 Oct; 34():276-80. PubMed ID: 9417349
    [Abstract] [Full Text] [Related]

  • 29. [Platelet transfusion from HPA typed donors in alloimmune thrombocytopenia of newborns and fetuses].
    Maślanka K, Zupańska B, Debski R, Jakubowska M, Radomska I, Dzieciatkowska A.
    Acta Haematol Pol; 1994 Oct; 25(3):215-20. PubMed ID: 7992593
    [Abstract] [Full Text] [Related]

  • 30. [Managing of platelet transfusion refractoriness of haematological malignancies. Experience IPC-EFSAM].
    Dettori I, Ladaique P.
    Transfus Clin Biol; 2014 Nov; 21(4-5):207-9. PubMed ID: 25267204
    [Abstract] [Full Text] [Related]

  • 31. The alloimmunized patient: effective transfusion support and newer experimental approaches.
    Pamphilon DH.
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):651-4. PubMed ID: 1450334
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Establishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China.
    Xia WJ, Ye X, Tian LW, Xu XZ, Chen YK, Luo GP, Bei CH, Deng J, Santoso S, Fu YS.
    Transfus Med; 2010 Aug 01; 20(4):269-74. PubMed ID: 20136782
    [Abstract] [Full Text] [Related]

  • 34. Identification of platelet refractoriness in oncohematologic patients.
    Ferreira AA, Zulli R, Soares S, Castro Vd, Moraes-Souza H.
    Clinics (Sao Paulo); 2011 Aug 01; 66(1):35-40. PubMed ID: 21437433
    [Abstract] [Full Text] [Related]

  • 35. [Transfusion-refractory thrombocytopenia during chemotherapy: pathogenesis, frequency and treatment].
    Helleberg C, Taaning EB, Johnsen HE.
    Ugeskr Laeger; 1995 Sep 11; 157(37):5082-6. PubMed ID: 7502374
    [Abstract] [Full Text] [Related]

  • 36. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y, Li W, Liu N, Zhang K, Gong Z, Li D, Wang L, Wang D, Jing Y, Wang J, Shan X.
    Transfus Med; 2014 Dec 11; 24(6):406-10. PubMed ID: 25327352
    [Abstract] [Full Text] [Related]

  • 37. Non-Alloimmune Mechanisms of Thrombocytopenia and Refractoriness to Platelet Transfusion.
    Belizaire R, Makar RS.
    Transfus Med Rev; 2020 Oct 11; 34(4):242-249. PubMed ID: 33129606
    [Abstract] [Full Text] [Related]

  • 38. Platelet antibodies.
    Pulkrabek SM.
    Clin Lab Med; 1996 Dec 11; 16(4):817-35. PubMed ID: 8974197
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions.
    Abraham AS, Chacko MP, Fouzia NA, Srivastava A, Daniel D.
    Transfus Med; 2018 Oct 11; 28(5):392-397. PubMed ID: 29460307
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 51.